Research paper

Bhlhe40 differentially regulates the function and number of peroxisomes and mitochondria in myogenic cells

Hsuan Chia Chang¹, Chien Han Kao¹, Shih Ying Chung, Wei Cheng Chen, Lulus Putri Aninda, Yi Huan Chen, Yi An Juan, Shen Liang Chen*  
Department of Life Sciences, National Central University, Jhongli, Taiwan, ROC

ARTICLE INFO

Keywords:  
Skeletal muscle  
Bhlhe40  
PGC-1α  
Oxidative metabolism  
Peroxisome

ABSTRACT

PGC-1α is a key regulator of oxidative metabolism facilitating the expression of genes critical for the function and biogenesis of the two key oxidative organelles, mitochondria and peroxisomes, in skeletal muscle (SKM) and other organs. Our recent studies have found that the transcription factor Bhlhe40 negatively regulates PGC-1α gene expression and its coactivational activity, therefore, this factor should have profound influence on the biogenesis and metabolic activity of mitochondria and peroxisomes. Here we found that both the number and activity of peroxisomes were increased upon knockdown of Bhlhe40 expression but were repressed by its over-expression. Mitochondrial efficiency was significantly reduced by Bhlhe40 knockdown, resulting in the burst of ROS. Over-expression of a constitutively active PGC-1α-interactive domain (named as VBH135) of Bhlhe40 mimicked the effects of its knockdown on peroxisomes but simultaneously reduced ROS level. Furthermore, the efficiency, but not the number, of mitochondria was also increased by VBH135, suggesting differential regulation of peroxisomes and mitochondria by Bhlhe40. Unsaturated fatty acid oxidation, insulin response, and oxidative respiration were highly enhanced in Bhlhe40 knockdown or VBH135 over-expressed cells, suggesting the importance of Bhlhe40 in the regulation of unsaturated fatty acid and glucose oxidative metabolism. Expression profiling of genes important for either organelle also supports differential regulation of peroxisomes and mitochondria by Bhlhe40. These observations have established the important role of Bhlhe40 in SKM oxidative metabolism as the critical regulator of peroxisome and mitochondrion biogenesis and functions, and thus should provide a novel route for developing drugs targeting SKM metabolic diseases.

1. Introduction

Skeletal muscle (SKM) relies very much on the transcriptional coactivator PGC-1α to promote oxidative metabolism, metabolic thermogenesis adaptation, biogenesis of mitochondria, and fatty acid oxidation for adapting to high energy demands [1–3]. In SKM, PGC-1α is preferentially expressed in oxidative metabolism dependent slow-twitch fibers [4] and its over-expression can convert putative fast-twitch fibers into slow-twitch fibers [4]. The expression of PGC-1α in skeletal muscle is critically regulated by transcription factors with bHLH DNA-binding motif, as it can be activated by myogenic regulatory factors (MRFs, including Myf5, MyoD, Myogenin and Mrf4) but repressed by Bhlhe40 [5]. However, this antagonism can be relieved when P/CAF, a key coactivator of MRFs, is supplied in over-dose, suggesting the sequestration of P/CAF by Bhlhe40 [6].

Bhlhe40 (also known as Stra13, Dec1, Sharp2, or BHLHB2) is ubiquitously expressed but with strong expression in skeletal muscle [7,8], where it regulates the activation of myogenic stem cells (named as satellite cells) by antagonizing Notch signaling [8] and protects SKM from reactive oxidative species (ROS) induced damage by activating the expression of heme-oxygenase-1 (HO-1) [9]. Multiple cellular processes, including differentiation, tumorigenesis, peripheral circadian output, and response to hypoxia, have been reported to involve Bhlhe40 [7,10–12]. Bhlhe40 can either function as a transcriptional repressor through both histone deacetylase (HDAC)-dependent and -independent mechanisms on most target genes [13] or as an activator on ðNp63 and Survivin genes [14,15].

Mitochondria and peroxisomes are the major organelles involved in the cellular oxidative metabolism and both are ubiquitous and highly dynamic. Mitochondria are the power houses of eukaryotic cells and they provide ATP currency through oxidative phosphorylation (OXPHOS) of reducing equivalents [16]. Peroxisomes participate in the
β-oxidation of very long chain, unsaturated, and branched fatty acids [17]. Additionally, they can also metabolize carboxylates containing a 3-methyl or 2-hydroxy group via α-oxidation, whereby the one-carbon shortened products can be passed onto the β-oxidation system. Another important function of peroxisomes is removing the harmful reactive oxygen species (ROS) concomitantly generates from the oxidation of substrates in mitochondria and peroxisomes, which is performed by several antioxidant enzymes, including Catalase, SOD1, and PRDX5.

It has been shown that PGC-1α play critical roles in the regulation of the biogenesis and function of mitochondria and peroxisomes through coactivating the activity of various DNA-binding transcription factors, such as PPARγ, ERα, and NRF1 [1,18]. Recently we found that PGC-1α directly interacted with Bhlhe40 and they co-occupied PGC-1α targeted gene promoters/enhancers, which in turn repressed PGC-1α transactivational activity [19]. Relief of this repression by knockdown of Bhlhe40 expression increased levels of ROS, fatty acid oxidation, mitochondria DNA, and the expression of PGC-1α target genes. These observations suggest that Bhlhe40 should be an important regulator of mitochondrial and peroxisome biogenesis and functions [19]. Therefore, more endeavor should be devoted to decipher the regulation of these two organelles by Bhlhe40.

2. Materials and methods

2.1. Plasmids

The plasmids pEGFP-N1-roGFP-PTS1 and –KillerRed-PTS1 were generous gifts from Dr. Marc Fransen (Katholieke Universiteit Leuven, Belgium) and their construction can be found in Fransen’s publication [20]. The expression vectors of PGC-1α and Bhlhe40 and their promoters driven reporters have been described in our previous studies [19,21]. A Tet-off expression vector, pCEGFP-TRE, was created by inserting the Salt/Mul fragment of pBI-EGFP vector into the BglII/HindIII sites of pCDNA3 vector. The CDS of Bhlhe40-Flag or VP16-Bhlhe40-(1–135) was inserted into the EcoRV site of pCEGFP-TRE for stable cloning and doxycycline repressible expression. The basic region (ETYKLPHRLIEKKRR) of the DNA-binding motif in VBH135 was mutated into ETYALPAALIEKAAA by site-directed PCR mutagenesis before inserted back to the EcoRV site of pCEGFP-TRE vector to generate pCEGFP-TRE–VBH135m. The coding sequence of RFP was PCR amplified from PLKO-RFP vector with primers containing PTSE sequence in the N-terminus and inserted into the EcoRV site of the pCDNA3.0 vector. The CDSs of PPARγ, Bhlhe40, and PGC-1α carried in pCDNA3.0 vector were used for transient transfection assays (Fig. 4). The reporters driven by UCP-1 and M-cadherin promoters were in pGL3-basic and pStable-luc vectors, respectively.

2.2. Cell culture, promoter assay, and stable transfection

The detailed protocol of cell culture and promoter assay has been reported in our previous studies [19,21,22]. Briefly, C2C12 myoblasts were kept in DMEM containing 20% FCS and induced to differentiate to changing differentiation medium (DM) containing DMEM supplemented with 2% horse serum. Myotubes (MT) were examined after 4 days in DM (DM4) unless otherwise indicated. Fusion index indicates the percentage of nuclei in the myotubes among all nuclei and was calculated by the equation: nuclei in myotubes/total nuclei.

For promoter assay, reporter constructs (0.67 μg/well) and expression vectors (0.16 μg each/well) were transfected into myoblasts (70% confluence) grown in 12-well dish by T-Pro NTR-II transfection reagent. The expression or luciferase activity of each reporter construct driven by the respective promoter or transactivator (tTA) was normalized to that of Gapdh, which was used as internal control amplified in each reaction (Ct was determined from a standard curve). The expression level of Gapdh and the relative expression level of each gene in Bhlhe40 knockdown or overexpressed cells was calculated using the equation (2^(-ΔΔCt)). All observations were performed in triplicates and repeated at least 3 times.

For establishing the Tet-off stable clones, the tetracycline controlled transactivator (tTA) expression vector pcEF-tTA-RES-puro (5 μg/well) was transfected into C2C12 myoblasts and selected with puromycin (2.5 μg/ml) for 2–3 weeks. Then, pCEGFP-TRE vector (5 μg/well) carrying Bhlhe40, VBH135, or VBH135m was transfected into the tTA expressing cells and selected with G418 (800 μg/ml) for 2–3 weeks until stable clones were acquired.

2.3. Gene knockdown by lentivirus expressing shRNA

For establishing Bhlhe40 knockdown clone, pCMV-Δ8.91 (5.625 μg), pMD.G (0.625 μg), and the shRNA expressing pLKO1 vectors (6.25 μg) were transfected into 293FT cells (on a 10 cm dish) to generate infectious lentivirus, which was collected 48 h later before added to C2C12 culture medium. Infected C2C12 myoblasts were selected with puromycin (2 μg/ml) for at least 2 weeks to generate monoclonal colonies and these clones were expanded and examined for their Bhlhe40 levels with RT-PCR. Clones derived from pLKO1–218239 plasmid (clone ID TRCN0000218239) showed reduced Bhlhe40 level were used for further experiments. For transient knockdown of PGC-1α, viruses derived from pLKO1–218239 plasmid (clone ID TRCN0000218239) were pooled and used for infection. All vectors used for the knockdown experiments were purchased from the RNAi core facility of Academia Sinica.

2.4. Quantitative RT-PCR (qRT-PCR)

C2C12 cells were lysed with home-made Solution D (4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, 0.1% β-mecaptoethanol) and the genomic DNA and proteins were removed by repeated (x4) acid phenol/chloroform extractions and followed by ethanol precipitation of total RNA [23]. The detailed protocol for traditional and quantitative RT-PCR has been described in our previous studies [21,22]. Briefly, the first strand of cDNA was synthesized using the Superscript III kit (Invitrogen) according to the manufacturer’s protocol. All qPCR was performed in a 15 μl reaction mixture containing 5 μM forward/reverse primers, template cDNA (equivalent to about 25, 50, or 100 ng of total RNA was used in separate tubes to ensure the linearity of PCR amplification), and 1X SYBR Green reaction mix (Power SYBR Green PCR master mix, Applied Biosystems) for detecting PCR product. GAPDH was used as internal control amplified in the same PCR assay. The expression level of each gene was normalized to that of GAPDH first, then, the normalized expression level (2^(-ΔΔCt)) in control cells was arbitrarily set as 1, and the control cell ΔCt was deduced from those of the treatment groups to derived ΔΔCt. The relative expression level of each gene in Bhlhe40 knockdown or overexpressed cells was calculated using the equation (2^(-ΔΔCt)). All reactions were performed in ABI 7300 sequence detection system. The primer sets used are listed in supplementary table I.

2.5. Determination of ROS levels

The detailed protocols for these assays have been described in our previous study [19]. Cells were grown in 6-well plates until confluent before used assays. For measuring ROS, cells were incubated in KRPH buffer (20 mM HEPES at pH 7.4, 5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl, 4.7 mM KCl, and 1% BSA) containing 30 μM H2DCFDA for 30 min. Then, cells were extensive wash with PBS before trypsinized (with 0.25X trypsin) and re-suspended in PBS buffer. The fluorescence of H2-DCFDA in the cells was measured with a fluorescence spectrophotometer (Hitachi F-4500) and normalized with cell number.
2.6. Fatty acid oxidation

For measuring fatty acid oxidation, BSA conjugated 2 μCi 3H-labeled oleic acid (NET289005MC, Perkin Elmer) and palmitic acid (NET043001MC, Perkin Elmer) was added into cells kept in αMEM and incubated for 6 h in the presence of 100 μM cold oleic or 50 μM palmitic acid, respectively. Then, medium was collected and extracted with phenol/chloroform to remove un-metabolized 3H-palmitic acid or oleic acid as reported before [24]. The 3H activity in the aqueous phase was determined by a scintillation β-counter (LS6500, Beckman).

2.7. O₂ consumption

The Winkler test for determining dissolved O₂ level was performed as previously described [25]. Briefly, after one hour of incubation, 3 ml medium was transferred to a 15 ml centrifuge tube before 500 μl 1 M MnSO₄ and 500 μl mixture of 1 M KI and 6 N NaOH (1:3 vol: vol) was added, then mixed well until a brown precipitate of Mn₃⁺ appeared.
The Mn$^{3+}$ brown precipitate was dissolved by adding 500 μl 6 N HCl until the solution turned into a deep yellow color. Then, 500 μl 1% starch solution was added to serve as an indicator of I$_2$ before titrating with 18 mM S$_2$O$_3^{2-}$ to reduced I$_2$ and I$_3^-$ to I$^-$ until the solution turned clear. The amount of dissolved oxygen in the original medium can be deducted from the following equations: (1) 2 M S$_2$O$_3^{2-}$ could reduce 1 M I$_2$, and (2) 1 M I$_2$ was produced from costing 0.5 M O$_2$. Therefore, the net equation was that 1 mol dissolved oxygen was required to titrate with 4 mol S$_2$O$_3^{2-}$. The result was normalized to protein content and showed as nM O$_2$/mg/h.

2.8. Glucose uptake

The assay of glucose uptake was modified from previously described protocol [26]. Serum starvation was performed in HBSS (5 mM glucose) for at least 4 h to further enhance the basal and insulin-induced glucose uptake. After starvation, the culture medium of myotubes in 6-well plates were replaced with Krebs-Ringer phosphate (KRPH) buffer containing 0.2 μCi 2-deoxy-D-[3 H]-glucose (2-DG; NET328A250UC, Perkin Elmer) with/without 100 nM insulin and incubate at 37 °C for another 2 h. One well was treated with 10 μM cytochalasin B (CB) for inhibiting actin cytoskeleton mediated glucose uptake and thus served as non-specific/negative glucose uptake control. After two times wash with cold 1x phosphate-buffered saline (PBS), cells were lysed with 500 μl radioimmunoprecipitation assay (RIPA) buffer. The radioactivity in the lysate is quantified by liquid scintillation counting. The value of the result is normalized to protein amount and showed as cpm/μg.

2.9. NAD(P)H content

This assay was performed as previously described [27]. Briefly, cells grown on 6-well plates were harvested by trypsinization and suspended in PBS. Cell numbers were counted on hemocytometer and their emission of 460 nm light after excited with 340 nm light was determined using the F-4500 fluorescence spectrophotometer (Hitachi).

2.10. Mitotracker staining and Mitochondrial DNA level determination

Cells grown on 6-well plates were washed with PBS thoroughly before incubated with KRPH buffer containing MitoTracker Red CMXRox (50 ng/ml) for 30 min. Then cells were trypsinized and re-suspended in PBS. Cell numbers were counted on hemocytometer and their emission of 595 nm light after excited with 575 nm light was determined using the F-4500 fluorescence spectrophotometer (Hitachi) normalized with cell number. The relative amounts of mitochondria in the cells were determined by qRT-PCR using the ratio of mitochondrial genes (cytochrome b and Cox II) and nuclear genes (MyoD and Oct4) derived from total genomic DNA. The nuclear gene levels served as input control.

2.11. Catalase activity assay

The assay was modified from previous studies [28]. Briefly, C2C12 cells were harvested by trypsinization and re-suspended in PBS. Then cells were lysed by repeated passing through gauge #27 needle and examined under microscope for cellular fragmentation. The protein
concentration was determined with BCA protein assay and 0.1 μg total lysate was included in the 100 μl PBS based reaction mixture (10 mM H₂O₂ and with or without 20 mM catalase inhibitor 3-amino-1, 2, 4-triazole). Various times (5, 10, or 20 min) after the reaction, residual H₂O₂ level was determined with HRP conjugated IgG in the presence of equal amount enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech) in a Clarity 2 luminometer (BioTEK; Winooski, VM). For reactions containing 3-amino-1, 2, 4-triazole (3AT), lysate and 3AT were pre-incubate for 20 min to ensure the inhibition of catalase by 3-AT.

2.12. SDH assays

This assay was performed as previously described [29]. Briefly, cells were harvested by lifting in PBS containing 2 mM EDTA and washed extensively with PBS before sonicated to lyse the cells. After centrifugation, the protein concentration in the supernatant was determined by BCA reaction and equal amount (50 μg) of protein was used for enzymatic assays. For SDH assay, lysate, sodium succinate (40 mM, pH > 7), sodium azide (8 mM), and 2, 6-dinitrophenolindophenol (DCPIP, 0.005%) were incubated at 37 °C for

Fig. 3. The effects of Bhlhe40 over-expression on differentiation and metabolism. A Tet-off system was established to stably over-express Bhlhe40 and GFP simultaneously in C2C12 cells (C2C12-Bhlhe40), in which the expression is shut off in the presence of Doxycycline (Dox, 25 ng/ml). The expression of Bhlhe40 mRNA (left panel) and protein (right panel) in myoblasts is shown in (A) and its effects on myogenic differentiation (B) was represented by the fusion index (nuclei number in myotubes/total nuclei number). The effects on mtDNA levels of CMB and MT cells, and on Mitotracker stain intensity, SDH activity, and ROS levels in myotubes are shown in (C), (D), (E), and (F), respectively. (G) Images of C2C12-Bhlhe40 myoblasts transfected with KillerRed-PTS1 expression vector and counterstained with DAPI. The distribution (%) of cells with different numbers of peroxisome/cell and the average peroxisome number/cell are shown in (H) and (I), respectively. * and **: p < 0.05 and p < 0.01 vs. Dox (+) cells.
30–60 min before SDS (2%) was added to stop the reaction. The reaction product was determined by reading absorbance at 600 nm in a spectrophotometer.

2.13. SOD assay

Samples for SOD2 assay was processed as in the SDH assay, and the SOD activity was determined using a SOD assay-WST kit (19160–1KT, Sigma) according to the manufacturer’s protocol. Briefly, lysate was mixed with WST and enzyme solutions at 37 °C for 20 min. Then, the reaction product was determined by reading absorbance at 450 nm in a spectrophotometer. The SOD activity in the lysate was calculated by the percentage of reduction in the 450 nm absorbance.

2.14. Western blot

The detailed Western blot protocol has been described previously [30]. Briefly, aliquots of total lysate (50 μg) in RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors were run on 10% SDS-PAGE gels before blotted onto a PVDF membrane (Pall FluoroTrans W membrane, PALL). After extensively washed with 1X PBS containing 0.5% Tween 20 (PBST), PVDF membranes were blocked by 5% skimmed milk in PBST for 30–60 min. Primary antibody was diluted 1:10000 in blocking solution and incubated with the blot at 4 °C for overnight. After several washes with PBST, HRP conjugated secondary antibody (1:10000 dilution) was added and incubated at room temperature for 1 h. After extensive wash, the HRP signal was detected by an enhanced chemiluminescence kit (Amersham Pharmacia Biotech). The Flag antibody was purchased from Sigma (M2 antibody, F3165), and the rabbit polyclonal antibody against Bhlhe40 amino acids 259–411 was generated in our laboratory [19]. The antibodies for SDHB2, Gapdh, Lamin B1, OXPHOS subunits, MTCO1, and MTCO2 were from Abcam (ab178423, ab9482-200, ab16043-25, ab110413, ab1475, and ab198286, respectively).

2.15. Statistic analyses

All experiments were performed at least 3 times with similar results observed. Results from independent experiments were pooled and their means and standard errors are shown. The difference between various treatments was examined with student’s t-test. All tests were 1-sided, and a probability value of < 0.05 was considered statistically significant. For real-time PCR, each assay was performed in duplicate of two different input levels to ensure linear PCR amplification and no difference in ΔCt between input levels should be detected.

2.16. Detection and counting of peroxisomes

The peroxisome reporter plasmids (pEGFP-N1-roGFP-PTS1, -KillerRed-PTS1, and pCDNA3-RFP-PTS1) were transfected into C2C12...
myoblasts (about 40–50% confluence) grown on glass cover slides held in 12-well dishes for overnight, then medium was changed and cells were harvested 48 h later. Cells were washed 3 times with PBS before fixed in in 4% paraformaldehyde for 30 min. After fixation, cells were washed 3 times with PBS and then quenched in PBS containing 50 mM NH₄Cl. To visualize the nuclei, cells were incubated with DAPI (2 μg/ml in PBS) at room temperature for 10 min and were washed with PBS thoroughly afterward. All the images were observed and photographed under a Carl Zeiss Axio Observer A1 fluorescence microscope with AxioVision software. The peroxisome numbers on photographed images were counted either manually (Figs. 1 and 2) or automatically using the Image J software (Fig. 6). The reliability of this assay was confirmed by the overlapped images of RFP-PTS1 and Catalase detected by immunofluorescence (Supplementary Fig. 3).

2.17. Immunostaining

After in DM for 72–96 h, stable clone cells were washed with cold PBS before fixed in 4% paraformaldehyde for 20 min. Then, they were quenched in 50 mM NH₄Cl for 15 min before permeabilized in 2% Triton-X 100 overnight. Cells were incubated in blocking solution (2% BSA and 2% goat serum in PBS) for 20 min followed by incubating with MHC antibody (1: 1000 dilution; clone MY-32, Sigma) over night. After extensive wash with PBS, HRP-conjugated secondary antibody (Goat anti mouse IgG, Santa Cruz) was added and incubated for an hour. The expression of MHC was visualized with AEC substrate kit (Zymed Laboratories) and the cells were counter-stained with hematoxylin and eosin.

For immunofluorescent staining of Catalase, cells were processed as above but with the Catalase antibody (SC-271803, Santa Cruz) and FITC-conjugated secondary antibody (ab6785-1, Abcam) used. To visualize the nuclei, cells were incubated with DAPI at room temperature for 10 min after the secondary antibody incubation and were washed with PBS thoroughly afterward. All the images were observed and photographed under the Carl Zeiss Axio Observer A1 fluorescence microscope with AxioVision software.

3. Results

3.1. Bhlhe40 is a critical regulator of mitochondrion and peroxisome activity

Mitochondria (MITO) are the power houses of a cell and it is of interest to know if their functions and number are regulated by Bhlhe40; therefore, stable clones of Bhlhe40 knockdown cells, C2Cl2-shBhlhe40, were established (Supplementary Fig. 1A). Our previous data had shown that mitochondrial DNA (mtDNA) was increased in C2Cl2-shBhlhe40 cells [21]; however, here we were surprised to find that their staining intensity of Mitotracker, an inner membrane potential dependent MITO stain, was significantly reduced (Fig. 1A & B). As their relative membrane potential/efficiency (mitotracker stain normalized by mtDNA level) was also reduced (Fig. 1C and Supplementary Fig. 1B), it indicates deficiency of MITO functions amid increased mtDNA and MITO number. The deficiency of MITO functions was further demonstrated by the radical increase in cellular ROS level but reduced SDH activity and the expression levels of oxidative...
phosphorylation system (OXPHOS) subunits (Fig. 1D, E & F). Surprisingly, the OXPHOS complex IV subunit MTCO1 (Fig. F), but not MTCO2, was highly induced in C2C12-shBhlhe40 cells, implying unbalance of this OXPHOS complex. Whether surged MTCO1 protein was the cause of ROS increase or secondary to it needs to be further investigated.

Another important oxidative organelle and ROS contributor is the peroxisome, but whose number is difficult to quantify due to the lack of DNA in this organelle. The quantification difficulty was overcome by the use of PTS1-roGFP protein that specifically localized to peroxisomes and light up them with green light. After counting these green dots in the cells, we found the number of peroxisomes was significantly increased in the C2C12-shBhlhe40 cells (Fig. 1G~I), suggesting the shift from MITO-dependent to peroxisome-dependent oxidative metabolism. We further found that the ROS level in C2C12-shBhlhe40 could be increased by palmitic acid (PA), a MITO-dependent saturated fatty acid, in a dose-dependently manner (Fig. 2A), but not by oleic acid (OA), an unsaturated fatty acid depending on peroxisome for its metabolism.

Fig. 6. The effects of VBH135 or VBH135m over-expression on mitochondrion and peroxisome activity. The levels of ROS, mtDNA, and Mitotracker stain intensity of C2C12-VBH135 and -VBH135m cells at CMB and MT stages in the presence and absence of Dox are shown in (A), (B), and (C), respectively. The MITO efficiency (D) was calculated by Mitotracker/mtDNA and compared with cells treated with Dox (+). (E) Images of C2C12-VBH135 and -VBH135m myoblasts transfected with RFP-PTS1 expression vector and counterstained with DAPI. The average number of peroxisomes/cell (F) and the distribution (%) of cells with different numbers of peroxisome/cell (G & H) of peroxisome number/cell are calculated 48 h after transfection. * and **: p < 0.05 and p < 0.01, respectively, vs. Dox (+) cells.
Knockdown of Bhlhe40 significantly enhanced oxidative respiration but which was compromised by PA treatment (Fig. 2C). On the contrary, insulin stimulated glucose uptake and response were reduced in C2C12-shBhlhe40 cells (Fig. 2D and Supplementary Fig. 1C), although the insulin signaling pathway was not affected (Supplementary Fig. 1D). These observations suggest the shifting from glucose-dependent metabolism to other energy sources, which was further confirmed by the discovery that the NAD(P)H, important cofactors for fatty acid metabolism, level in these cells was significantly increased (Fig. 2E), suggesting for increased fatty acid metabolism.

3.2. Over-expression of Bhlhe40 reduces peroxisome number

A doxycycline (Dox) regulated inducible system (Tet-off) of Bhlhe40 was established (Fig. 3A) to discuss the effects of its over-expression on MITO and peroxisome activity. We found that the C2C12-Bhlhe40 cells differentiated normally (Fig. 3B and Supplementary Fig. 2B) and neither mtDNA level nor Mitotracker stain intensity was altered in these cells (Fig. 3C, D & Supplementary Fig. 2A), indicating no observable effect on MITO number and function, which is further confirmed by unaltered SDH activity (Fig. 3E). However, the level of ROS and number of peroxisomes were both reduced by Bhlhe40 over-expression (Fig. 3F–I). We further examined their SOD activity and found marginal but significant increase by Bhlhe40 overexpression (Supplementary Fig. 4A). These observations suggest that Bhlhe40 is an important negative regulator of cellular peroxisome number and ROS level.

3.3. VBH135 serves as an antagonist of Bhlhe40

One of the mechanisms employed by Bhlhe40 to regulate cellular oxidative metabolism is repressing the coactivational activity of PGC-1α via direct interaction with each other's N-terminal domains [19]. The N-terminal domain (1–135 amino acids) of Bhlhe40 mediate strong interaction with PGC-1α without affecting its coactivational activity on PPARγ activated UCP1 promoter driven luciferase reporter (Fig. 4A). Fusion of this domain with VP16 activation domain creates a constitutively active factor (VBH135, Fig. 4B) that can rescue wildtype Bhlhe40 repressed PGC-1α coactivational activity (Fig. 4C). As this domain retains the DNA-binding domain of Bhlhe40, it raises the query whether it can also bind to Bhlhe40 target genes to activate their expression? We have reported that M-cadherin promoter can be repressed by Bhlhe40 [21], and with this promoters we found strong activation by VBH135 and which can further overcomes the repression by wildtype Bhlhe40 (Fig. 4D). As the DNA-binding mutant of VBH135 (VBH135m) failed to affect M-cadherin promoter activity, suggesting that VBH135 can be used as a Bhlhe40 antagonist to rescue its repression of PGC-1α- and Bhlhe40-targeted gene expression via protein-protein interaction and direct DNA-binding.

3.4. VBH135 increases the efficiency of both MITO and peroxisomes

VBH135 and its DNA-binding domain mutant were stably over-expressed in C2C12 using the Tet-off system, and their mRNA and protein could be induced by removal of Dox (Fig. 5A & B, Suppl. Fig. 2C, and in
We further found that their expression did not affect myogenic differentiation (Fig. 5C & Suppl. Fig. 2C), so their effects on SKM metabolism would not be complicated by that on differentiation.

Although VBH135 over-expression had no effect on terminal differentiation, significantly reduced levels of ROS, mtDNA, and Mitotracker stain were found in C2C12-VBH135 cells (Fig. 6A~C), however, these reducing effects were compromised in cells over-expressed with VBH135m, suggesting the involvement of DNA-binding ability of VBH135 in its metabolic regulation. The MITO efficiency was found increased by VBH135 (Fig. 6D), which partially explained the cause of reduced ROS and Mitotracker stain, since only high efficient mitochondria remained. Unexpectedly, the mtDNA level was increased, but the MITO efficiency was reduced, in confluent C2C12-VBH135m myoblasts (Fig. 6B~D), implying that DNA-binding independent protein-protein competition of VBH135m with some factors, such as PGC-1α, negatively affected MITO functions in myoblasts, but not in myotubes. On the contrary, the regulation of peroxisome number by VBH135 was more DNA-binding dependent as it was significantly increased by VBH135, but not VBH135m, in confluent myoblasts (Fig. 6E~H).

The effects of VBH135 expression on metabolism were analyzed and we found that Catalase activity was enhanced by VBH135, suggesting for better peroxisome activity/efficiency (Fig. 7A). We further found that O2 consumption was highly increased by VBH135 (Fig. 7B), and

Fig. 8. The genes targeted by Bhlhe40 and VBH135. The genes expression patterns of C2C12-VBH135 and C2C12-Bhlhe40 myotubes and C2C12-shBhlhe40 myoblasts were examined with qRT-PCR. The relative levels of genes involved in peroxisome or mitochondrial biogenesis and functions are shown in (A) and (B) respectively. The results of genes involved in ROS scavenging are shown in (C). Binding of Bhlhe40 to target gene promoters was examined in C2C12-Bhlhe40 myotubes (Dox (-)) by ChIP assay (D). PGC-1α was knockdowned in C2C12-VBH135 (E) and -Bhlhe40 (F) myotubes to reveal PGC-1α-dependent gene regulation. * and **: p < 0.05 and p < 0.01, respectively, vs. Dox (+) or control cells. # and ##: p < 0.05 and p < 0.01 vs. control ShRNA treated Dox (+)/(-) in (E) and (F).
which was consistent with the increased oxidation of both PA and OA (Fig. 7C & D), implying more dependent on mitochondria and peroxisome mediated fatty acid oxidation. Surprisingly, although basal glucose uptake was slightly mitigated by VBH135, cellular response to insulin treatment was improved by it and the insulin induced glucose uptake was similar to control cells (Fig. 7E & F).

3.5. Differential regulation of the expression of key MITO and peroxisome regulators by VBH135 and Bhlhe40

To identify factors mediating Bhlhe40 effects on MITO and peroxisomes, the expression of key factors regulating the biogenesis and functions of MITO and peroxisomes was examined by quantitative RT-PCR (qRT-PCR). We found that the mRNA levels of factors involved in peroxisome biogenesis, such as Pex3, Pex16, and Pex19, protein import, such as Pex5 and Pex7, and fission, such as Pex11β, were significantly increased by VBH135 but reduced by Bhlhe40 (Fig. 8A). Similar effects were seen on the expression of PGC-1α and the key fatty acid metabolizing enzyme Acadl in peroxisomes. The expression of most peroxisome-related factors (except for Pex2) was also increased by Bhlhe40 knockdown.

Interestingly, the mRNA levels of most factors involved in mitochondrial replication or gene expression, such as Tfib1m, DNA polymerase γ (Polγ), and Twinkle, were repressed by both VBH135 and Bhlhe40, although other factors, such as MtSSB and RNA polymerase (Polmt), were only repressed by Bhlhe40 (Fig. 8B). NRF1, NRF2, and ERRo are transcription factors regulating MITO function and they are all upregulated by both VBH115 and Bhlhe40, implying indirect regulation. Bhlhe40 knockdown repressed Tfib1m and NRF1, but increased the expression of Twinkle, NRF2, and ERRo. Tfam expression was only activated by VBH135 but not altered by Bhlhe40 and its knockdown. The expression of ROS scavenging enzymes Catalase and HO1 was activated by VBH135 but reduced by Bhlhe40 as that of peroxisomal factors. SOD2, the major ROS scavenging enzymes in mitochondria, mRNA level was not affected by VBH135 but highly increased by Bhlhe40 (Fig. 8C). Both SOD2 and HO1 mRNA was enhanced by Bhlhe40 knockdown, and the SOD2 protein was also increased in this stable clone (Suppl. Fig. 4B). Furthermore, increased total SOD activity was found in C2C12-Bhlhe40 cells (Suppl. Fig. 4A). Taken together, the expression profiling results support the notion that VBH135 enhances the expression/activity.

The recruitment of Bhlhe40 to these target gene promoters was also examined with ChIP assay and strong binding of Bhlhe40 to promoters of all 3 categories of genes was detected, suggesting regulation of these genes by Bhlhe40 in vivo (Fig. 8D). It was of interest to know whether Bhlhe40 directly binding to cis-elements in these genes to regulate their expression or indirectly through repressing PGC-1α expression/activity. To clarify this issue, the expression of some key factors was examined in C2C12-VBH135 and -Bhlhe40 cells after PGC-1α knockdown. We are surprised to find that, after PGC-1α knockdown, all the activation effects of VBH135 was suppressed and the repression of Pex3, Pex11, Pex16, and Twinkle by Bhlhe40 disappeared, implying a PGC-1α-dependent regulation (Fig. 8E & F). The activation of SOD2 by Bhlhe40 was also compromised by PGC-1α knockdown, demonstrating a partially PGC-1α-dependent regulation. However, the repression of HO1 by Bhlhe40 remained after PGC-1α knockdown, suggesting HO1 might be regulated by Bhlhe40 without involving PGC-1α. These observations together demonstrated the importance of Bhlhe40-mediated PGC-1α regulation in cellular oxidative respiration and ROS metabolism.

4. Discussion

Although Bhlhe40 has been implicated in many cellular processes, including differentiation, tumorigenesis, peripheral circadian output, and response to hypoxia [7,10–12], its involvement in the regulation of mitochondrial and peroxisomal function and biogenesis has not been reported before. This study is the first one reporting its critical role in the regulation of these two organelles and should provide more support for its involvement in manys physiological processes as both organelles play critical roles in energy supply and adaptation.

Our current study found that mtDNA was slightly increased in C2C12-shBhlhe40 cells (Supplementary Fig. 1B) but not in C2C12-Bhlhe40 cells (Fig. 3C), implying the minor role of Bhlhe40 in the regulation of mitochondrial number. On the other hand, ROS level was increased in C2C12-shBhlhe40 cells but reduced in C2C12-Bhlhe40 and -VBH135 cells, which strongly implicates the involvement of Bhlhe40 in the suppression of ROS in SKM and sufficient amount of Bhlhe40 is required to maintain ROS under harmful level. Furthermore, the increased mtDNA level but reduced MITO efficiency in the C2C12-shBhlhe40 cells might reflect mitochondrial dysfunction caused by surged ROS level [33]. Both MITO and peroxisomes are the major sources of ROS and they contain separate sets of enzymes for detoxification of ROS, for instance, SOD2 (Mn-SOD) is functioning in MITO but Catalase, SOD1 (Cu/Zn-SOD), and Prdx5, are functioning in the peroxisomes [32]. The previously reported Bhlhe40 target gene HO1 is actually a cytoplasmic ROS scavenging enzyme. Our results suggest that HO1 is a bona fide repressive target of Bhlhe40 containing Bhlhe40-binding sites in its regulatory cis-elements, but Catalase and SOD2 might be regulated by Bhlhe40 via antagonizing PGC-1α activity (Fig. 8D & E). These results suggest that Bhlhe40 regulates intracellular ROS level mainly by activating the expression of one set of ROS scavenging enzymes but repressing the expression of others, either directly or indirectly through PGC-1α. Under the condition of low Bhlhe40 expression, such as in C2C12-shBhlhe40, the expression of these activating targets is reduced, which in turn results in the accumulation of ROS and dysfunction of MITO.

Although it has been reported before that HO1 is activated by Bhlhe40, but evidence showing direct regulation of HO1 promoter or other cis-elements by Bhlhe40 is still lacking [9]. As the previous observation is contradictory to our current observations, further study on its promoter regulation by Bhlhe40 is required to solve this contradiction. The repressor role of Bhlhe40 has been studied in many genes, and it binds to the B class E-box (CAGCGT) as homodimer instead of the N-box (CACCGC) on the promoters/enhancers of these genes [33]. Using bioinformatics tool, multiple E-boxes can be identified in the HO1 promoter region, and we are currently trying to dissect their function in the Bhlhe40 mediated repression of HO1.

It has been shown that Bhlhe40 protects muscle cells from oxidative damage and its absence leads to muscle necrosis in response to injury, a phenomenon usually associated with Duchenne Muscular Dystrophy [9]. These can be demonstrated by the Bhlhe40-/- mice, where the levels of TNFa is increased but the level of HO1 is reduced and apparent signs of oxidative stress is shown before muscle death. Its role in SKM protection can be further perceived as it is induced by genotoxic stress and hypoxia, two conditions that are associated with exercise [34]. As Bhlhe40 can function as a transcriptional activator and repressor, like the two blades of a sword, genes involved in producing genotoxic stress can be repressed by Bhlhe40 and those involved in scavenging ROS should be activated by Bhlhe40. The induction of SOD2 but repression of Catalase and HO1 by Bhlhe40 indicates that Bhlhe40 selectively activates some ROS scavenging enzymes but repress the others. Although PGC-1α level is increased in the C2C12-shBhlhe40 cells (Fig. 8), the ROS level still surged significantly (Fig. 2A & B), implying PGC-1α-independent activation of ROS scavenging enzymes by Bhlhe40 should play an important role in Bhlhe40-mediated ROS reduction. Further investigating on its regulation of other ROS scavenging enzymes, such as SOD1 and those in the peroxisomal systems (including the thioredoxin/thioredoxin reductase/peroxiredoxin and the glutathione/glutathione peroxidase systems), should provide better insight into how ROS level is regulated by Bhlhe40.
Bhlhe40 has been shown to repress adipocyte differentiation via repressing the key adipogenic factor, PPARγ2, so its role in negative regulation of fatty acid oxidation in adipocytes is predictable [35]. Its negative role in fatty acid oxidation is also found in myocytes, but its mechanism remain elusive [36]. Our previous study had shown the enhanced fatty acid oxidation in C2C12-VBH135 and -shBhlhe40 cells, and the expression of factors participating in oxidation of fatty acids in mitochondria was also increased in these cells [19]. Here we further demonstrated that Bhlhe40 can also negatively regulate the expression of factors involved in peroxisomal fatty acid oxidation and in the biogenesis of peroxisomes (Fig. 8). As Bhlhe40 is ubiquitously expressed so its role in tissues with low PGC-1α expression, such as liver and spleen [37], should be further assessed to reveal the participation of its PGC-1α-independent regulation of fatty acid metabolism in these tissues.

The number of peroxisomes in a cell reflects its metabolic status and it is balanced by the biogenesis and autophagy (or pexophagy for peroxisomes) processes. The number of peroxisomes can be increased, through either fission of existing peroxisomes or de novo biogenesis from ER derived membrane, by treating cells with peroxisome proliferator, such as fibrates, or its substrates, such as oleic acid (an unsaturated fatty acid) to switch the metabolic dependence to peroxi


dependent metabolism [17]. Our observations here suggest that Bhlhe40 targets both mitochondria and peroxisomes oxidative metabolism, but only negatively regulates the number of peroxisomes by reducing the expression of its key biogenic factors. This peroxisome-specific regulation seems to be independent of PGC-1α as PGC-1α is deeply involved in the function and biogenesis of both organelles [1,18]. Further study on the regulation of peroxisome biogenesis genes by Bhlhe40 should shed light on this PGC-1α-independent biogenesis pathway. Besides, the fission of peroxisomes is probably mildly or not targeted by Bhlhe40 as the expression of Pex11 and factors in the fission machinery (shared with mitochondria) is only mildly affected by both VBH135 and Bhlhe40 (Fig. 8 and data not shown).

Most obsolete peroxisomes (about 80%) are degraded through pexophagy [38], in which both Pex14, a component of the Pex5 PTS-1 receptor docking complex, and ubiquitinated peroxisome membrane proteins (Ub-PMPs, such as Pex5 and PMP70), can trigger pexophagy [39–41]. The ubiquitination of PMPs is majorly mediated by Pex2, an E3 ubiquitin ligase in the Pex2/Pex10/Pex12 translocation complex, which then recruits the autophagic adaptor p62/NBR1 and receptor LC3 to initiate pexophagy [42]. Under starvation, Pex14 can directly interact with LC3-II, the phosphatidylethanolamine conjugated and active form of LC3, to activate pexophagy. As Bhlhe40 negatively regulates pexophagy number, it will be interesting to know whether pexophagy is enhanced by Bhlhe40 under normal and pathologic conditions.

Bhlhe40 is involved in many diverse physiological processes and also responses to various physiological stimuli. It can be induced by retinoic acid in p19 embryonic carcinoma stem cells, where it inhibits mesodermal, but promotes neuronal, differentiation [43]. Both parathyroid hormone and its 2nd messenger cAMP can induce Bhlhe40 mRNA in chondrocytes [44], but EGF can only accumulate Bhlhe40 protein in mammalian epithelium [45]. In breast cancer cells, Bhlhe40 is induced by TGFβ to mediate the anti-apoptotic effect [46]. It is highly induced by hypoxia and is highly augmented in most types of tumors, although reduced in some cases [7,12,47]. In tumor tissues examined, it is predominantly expressed in viable cells surrounding the necrosis tissues, suggesting its dual roles in response to hypoxia: induced by hypoxia to antagonize apoptosis but turns into an apoptotic factor in extreme hypoxia condition [12]. Bhlhe40 can also response to circadian rhythm, in which it is induced by Clock-Bmal1 proteins to regulate a subset of peripheral circadian output [11,48]. It can also be induced by insulin via PI3K pathway in the liver of diabetic mice [49]. The discovery of its implication in the regulation of mitochondrial and peroxisome functions and number in this study has provided a very sound answer to why/how it is involved in such a diverse range of physiological processes, as both organelles are metabolically required in these processes. Therefore, understanding its role in the regulation of both organelles is key to further understanding the regulation of these physiological processes. In the near future, more endeavor should be devoted to unravel the mechanisms by which Bhlhe40 employed to regulate nuclear/mitochondrial genes participating in peroxisome and mitochondrial functions and regulation, so novel drugs targeting SKM metabolic diseases can be developed.

Acknowledgements

The authors like to thank Dr. Marc Fransen (Katholieke Universiteit Leuven, Belgium) for providing roGFP-PTS1 and KillerRed-PTS1 expression vectors. We are also grateful to Dr. Shuang En-Chuang (National Health Research Institutes) for help with the promoter assays. Thanks also go to Drs. Hong-Chen Chen and Won-Jin Wang (Institute of Biochemistry and Molecular Biology, National Yang Ming University, Taiwan) for their help during revision. This study was supported by funding from the National Science Council of Taiwan, ROC to Shen Liang Chen [NSC-102-2311-B-008-003 andMOST 105-2311-B-008-001]. The authors have no conflict of interest to declare.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.redox.2018.10.009.

References

[1] Z. Wu, P. Puigserver, U. Andersonson, C. Zhang, G. Adelmant, V. Mootha, A. Troy, S. Cantley, B. Lowell, R.C. Scarpulla, B.M. Spiegelman, Mechanism controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1, Cell 98 (1999) 115–124.
[2] J.C. Yoon, P. Puigserver, G. Chen, J. Donovan, Z. Wu, J. Rhee, G. Adelmant, J. Stafford, C.R. Kahn, D.E. Granner, C.R. Newgard, B.M. Spiegelman, Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1, Nature 413 (2001) 131–138.
[3] B.N. Finck, D.P. Kelly, PGC-1 coactivators: inducible regulators of energy metabolism in health and disease, J. Clin. Invest. 116 (2006) 615–622.
[4] J. Lin, H. Wu, P.T. Tarr, C.Y. Zhang, Z. Wu, O. Boss, L.F. Michael, P. Puigserver, E. Isotani, E.N. Olson, B.B. Lowell, B.M. Spiegelman, Transcriptional coactivator PGC-1 alpha drives the formation of slow-twitch muscle fibres, Nature 418 (2002) 797–801.
[5] J.H. Chang, K.H. Lin, C.H. Shih, Y.J. Chang, H.C. Chi, S.L. Chen, Myogenic basic helix-loop-helix proteins regulate the expression of peroxisomal proliferator activated receptor-gamma coactivator-1alpha, Endocrinology 147 (2006) 3093–3106.
[6] S.P. Hsiao, K.M. Huang, H.Y. Chang, S.L. Chen, P./CAF rescues the Bhlhe40-mediated repression of MyoD transactivation, Biochem. J. 422 (2009)343–352.
[7] A.V. Ivanova, S.V. Ivanov, A. Danilkovitch-Margivka, M.L. Merman, Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9 ubiquitin proteasome degradation pathway, J. Biol. Chem. 276 (2001) 15306–15315.
[8] H. Sun, L. Li, C. Vercherat, N.T. Gulbagci, S. Acharjee, J. Li, T.K. Chung, T.H. Thin, R. Taneja, Stra13 regulates satellite cell activation by antagonizing Notch signaling, J. Cell Biol. 177 (2007) 647–657.
[9] C. Vercherat, T.K. Chung, S. Yalcin, N. Gulbagci, S. Gopinadhan, S. Gaffarri, R. Taneja, Stra13 regulates oxidative stress mediated skeletal muscle degeneration, Hum. Mol. Genet. 18 (2009) 4304–4315.
[10] F. Guillaumeau, S. Lacoche, S. Dulong, A. Greche-Cassiau, E. Filipski, X.M. Li, F. Levi, E. Berra, F. Delaunay, M. Tehoul, Altered Stra13 and Dec2 circadian gene expression in hypoxic cells, Biochem Biophysics Res Commun. 369 (2008) 1184–1189.
[11] A. Greche-Cassiau, S. Panda, S. Lacoche, M. Tehoul, S. Armi, V. Lautet, J.B. Hogenesch, R. Taneja, F. Delaunay, The transcriptional repressor STRA13 regulates a subset of peripheral circadian outputs, J. Biol. Chem. 279 (2004) 11411–11420.
[12] L. Turley, C.C. Wykoff, S. Troup, P.H. Watson, K.C. Gatter, A.L. Harris, The hypoxia-regulated transcription factor DECI (Stra13, SHARP-2) and its expression in human tissues and tumours, J. Pathol. 203 (2004) 808–813.
[13] H. Sun, R. Taneja, Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms, Proc. Natl. Acad. Sci. USA 97 (2000) 4058–4063.
[14] Y. Qian, Y.S. Jung, X. Chen, DeltaNp63a, a target of DECI and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation, J. Biol. Chem. 286 (2011) 12033–12041.
[15] Y. Li, M. Xie, J. Yang, D. Yang, R. Deng, Y. Wan, B. Yan, The expression of anti-apoptotic protein survivin is transcriptionally upregulated by DECI primarily.
through multiple sp1 binding sites in the proximal promoter, Oncogene 25 (2006) 3296–3306.

[16] V. Ribas, C. Garcia-Ruiz, J.C. Fernandez-Checa, Mitochondria, cholesterol and cancer cell metabolism, Clin. Transl. Med. 5 (2016) 22.

[17] M. Horsho, S. Yamashita, Y. Fujiki, Peroxisome homeostatic mechanisms of division and selective degradation of peroxisomes in mammals, Biochim. Biophys. Acta 1863 (2016) 984–991.

[18] A. Bagattin, L. Hugendubler, E. Mueller, Transcriptional coactivator PGC-1alpha promotes peroxisomal remodelling and biogenesis, Proc. Natl. Acad. Sci. USA 107 (2010) 20576–20581.

[19] S.Y. Chung, C.H. Kao, F. Villarroya, H.Y. Chang, H.C. Chang, S.P. Hsiao, G.G. Liou, J. Zhang, D.N. Tripathi, J. Jing, A. Alexander, J. Kim, R.T. Powell, R. Deef, J. Tait-Mulder, J.H. Lee, T.T. Paul, K.R. Pandita, V.K. Charaka, T.K. Pandita, M.B. Kastan, C.L. Walker, ATP functions at the peroxisome to induce pexophagy in response to RGS, Nat. Cell Biol. 17 (2015) 1259–1269.

[20] S.P. Hsiao, S.L. Chen, Myogenic regulatory factors regulate M-cadherin expression through multiple sp1 binding sites in the proximal promoter, Oncogene 25 (2006) 3296–3306.

[21] Z. Yun, H.L. Markert, R.S. Johnson, A.J. Giaccia, Inhibition of PPAR gamma 2 gene expression by the HIP-1-regulated gene DECI/Strai3: a mechanism for regulation of adipogenesis by hypoxia, Dev. Cell 2 (2002) 331–341.

[22] S. Takeshita, T. Suzuki, S. Kitayama, M. Moritani, H. Inoue, M. Itakura, Bcliffe-40, a potential diabetic modifier gene on Dmb1 locus, negatively controls myocyte fatty acid oxidation, Genes Genet. Syst. 87 (2012) 253–264.

[23] S.V. Chung, W.C. Huang, C.W. Su, K.W. Lee, H.C. Chi, C.T. Lin, S.T. Chen, K.M. Huang, M.S. Tsai, H.P. Yu, S.L. Chen, Fst06 and PGC-1alpha form a regulatory loop in myogenic cells, Biosci. Rep. 33 (2013).

[24] M. Komatsu, S. Waguri, T. Iwata, S. Murata, I. Tanida, J. Iakzi, N. Mizushima, Y. Ohsumi, Y. Uchiyama, E. Komunini, K. Tanaka, T. Chiba, Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice, J. Cell Biol. 169 (2005) 425–434.

[25] P.K. Kim, D.W. Hailey, R.T. Mullens, J. Lippincott-Schwartz, Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes, Proc. Natl. Acad. Sci. USA 105 (2008) 20567–20574.

[26] S. Hara-Kuge, Y. Fujiki, The peroxin Pex11p is involved in LC3-dependent degradation of mammalian peroxisomes, Exp. Cell Res. 314 (2008) 3531–3541.

[27] H.F. Teng, Y.L. Kuo, M.R. Loo, C.L. Li, H. Suo, H.S. Liu, K.H. Lin, S.L. Chen, Valproic acid enhances Oct4 promoter activity in myogenic cells, J. Cell Physiol. (2016).

[28] E817–E828.

[29] J. Zhang, D.N. Tripathi, J. Jing, A. Alexander, J. Kim, R.T. Powell, R. Deef, J. Tait-Mulder, J.H. Lee, T.T. Paul, K.R. Pandita, V.K. Charaka, T.K. Pandita, M.B. Kastan, C.L. Walker, ATP functions at the peroxisome to induce pexophagy in response to RGS, Nat. Cell Biol. 17 (2015) 1259–1269.

[30] G. Sargent, T. von Zutphen, T. Shatskeva, L. Zhang, V. Di Giovanni, R. Bandnma, P.K. Kim, PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation, J. Cell Biol. 214 (2016) 677–690.

[31] M. Boudjelal, R. Tanoea, S. Matsuura, P. Bouillet, P. Dolle, P. Chambon, Overexpression of Strai3, a novel reteinoic acid-inducible gene of the basic helix-loop-helix family, inhibits mesodermal and promotes neuronal differentiation of P19 cells, Genes Dev. 11 (1997) 2052–2065.

[32] M. Shen, T. Kawamoto, M. Teramoto, S. Mukhira, K. Fujimoto, W. Yan, M. Noshiro, Y. Kato, Induction of basic helix-loop-helix protein DECI (BHLHB2)/Strai3/Sharp2 in response to the cyclic adenosine monophosphate pathway, Eur. J. Cell Biol. 80 (2001) 329–334.

[33] B. St-Pierre, M. Cooper, Z. Jiang, E. Zackhenhaus, S.E. Egan, Dynamic regulation of the Strai3/Sharp/Dec bHLH repressors in murine embryophel, Dev. Dyn. 230 (2002) 841–844.

[34] Z. Yamada, H. Kawata, Z. Hoshn, T. Mizutani, K. Miyamoto, Insulin induces the expression of the SHARP-2/Strai3/DECI gene via a phosphoinositide 3-kinase pathway, J. Biol. Chem. 278 (2003) 30719–30724.